Dysfunctional DNA repair with subsequent genome instability and high mutational burden represents a major hallmark of cancer. In established malignant tumors, increased DNA repair capacity mediates resistance to DNA-damaging therapeutics, including cytotoxic drugs, radiotherapy, and selected small molecules including inhibitors of poly (ADP-ribose) polymerase (PARP), Ataxia Telangiectasia Mutated (ATM), ataxia telangiectasia and Rad3-related protein (ATR), and Wee1 kinase (Wee1). In addition, DNA repair deficiency is not only associated with sensitivity to selected anticancer drugs, but also with increased mutagenicity and increased neoantigen load on tumor cells, resulting in increased immunogenicity and improved response to CTLA4- or PD-(L)1 targeting monoclonal antibodies. DNA damage response (DDR) is composed of complex signalling pathways, including the sensing of the DNA damage, signal transduction, cellular response pathways to DNA damage, and activation of DNA repair. DNA double strand breaks (DSBs) are the most dangerous form of DNA damage. Tumor cells are characterised by frequent accumulation of DSBs caused by either endogenous replication stress or the impact of cancer treatment, most prominently chemotherapy and radiotherapy. Therefore, response of cancer cells to DSBs represents a crucial mechanism for how tumors respond to systemic treatment or radiotherapy, and how resistance develops. Ample clinical evidence supports the importance of DDR associated kinases as predictive and prognostic biomarkers in cancer patients. The ATM-CHK2 and ATR-CHK1-WEE1 pathways initiate DNA DSB repair. In the current review, we focus on major DDR associated kinases including ATM, ATR, CHK1, CHK2, and WEE1, and discuss their potential prognostic and predictive value in solid malignancies.

ADMED Pathology Neuchâtel Switzerland

Clinic of Pediatry Faculty Hospital Olomouc Olomouc Czechia

Department of Clinical and Molecular Pathology Institute of Translational and Molecular Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Department of Medical Oncology and Haematology Cantonal Hospital St Gallen Switzerland

Zobrazit více v PubMed

Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: An orchestrated handover mechanism. Br J Radiol (2014) 87(1035):20130685.  10.1259/bjr.20130685 PubMed DOI PMC

Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J (2009) 423(2):157–68.  10.1042/BJ20090942 PubMed DOI PMC

Scully R, Xie A. Double strand break repair functions of histone H2AX. Mutat Res (2013) 750(1-2):5–14.  10.1016/j.mrfmmm.2013.07.007 PubMed DOI PMC

Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenetic Genome Res (2004) 104(1-4):14–20.  10.1159/000077461 PubMed DOI

Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene (2003) 22(37):5792–812.  10.1038/sj.onc.1206679 PubMed DOI

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature (2009) 461(7267):1071–8.  10.1038/nature08467 PubMed DOI PMC

Cimprich KA, Cortez D. ATR: An essential regulator of genome integrity. Nat Rev Mol Cell Biol (2008) 9(8):616–27.  10.1038/nrm2450 PubMed DOI PMC

Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol (2007) 19(2):238–45.  10.1016/j.ceb.2007.02.009 PubMed DOI

Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer (2003) 3(3):155– 68.  10.1038/nrc1011 PubMed DOI

Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 9(5):402– 12.  10.1038/nrm2395 PubMed DOI

Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature (2004) 432(7015):316– 23.  10.1038/nature03097 PubMed DOI

Huen MS, Chen J. The DNA damage response pathways: At the crossroad of protein modifications. Cell Res (2008) 18(1):8– 16.  10.1038/cr.2007.109 PubMed DOI

Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci (2016) 37(10):872– 81.  10.1016/j.tips.2016.06.006 PubMed DOI

Beck H, Nähse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, et al. Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption. Mol Cell Biol (2012) 32(20):4226–36.  10.1128/mcb.00412-12 PubMed DOI PMC

Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Silljé HH, de Vries EG, et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene (2013) 32(24):3001–8.  10.1038/onc.2012.296 PubMed DOI

Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, et al. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (2015) 17(10):757–66.  10.1016/j.neo.2015.09.006 PubMed DOI PMC

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 434:864–70. 10.1038/nature03482 PubMed DOI

Nakad R, Schumacher B. DNA damage response and immune defense: Links and mechanisms. Front Genet (2016) 7:1–10. 10.3389/fgene.2016.00147 PubMed DOI PMC

Chatzinikolaou G, Karakasilioti I, Garinis GA. DNA damage and innate immunity: Links and trade-offs. Trends Immunol (2014).  10.1016/j.it.2014.06.003 PubMed DOI

Mouw KW, D'Andrea AD. DNA Repair Deficiency and Immunotherapy Response. J Clin Oncol (2018) 36(17):1710–3.  10.1200/JCO.2018.78.2425 PubMed DOI

Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun (2017) 8(1):1751.  10.1038/s41467-017-01883-9 PubMed DOI PMC

Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005).  10.1038/nature03884 PubMed DOI PMC

www.cbioportal.org cBioportal for Cancer Genomics.

Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther (2016) 15:1781–91. 10.1158/1535-7163.MCT-15-0945 PubMed DOI

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, et al. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clin Colorectal Cancer (2018) 17(4):280–4.  10.1016/j.clcc.2018.05.011 PubMed DOI

Antonarakis ES, Kaur HB, Hicks J, Pritchard CC, De Marzo AM, Isaacs WB, et al. ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay. J Clin Oncol (2019) 37(15_suppl):5069–9.  10.1200/jco.2019.37.15_suppl.5069 DOI

Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, et al. ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget (2016) 7:57714–25. PubMed PMC

Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle (2017) 16:991–8.  10.1080/15384101.2017.1312236 PubMed DOI PMC

He H, Chang R, Zhang T, Yang C, Kong Z. ATM mediates DAB2IP-deficient bladder cancer cell resistance to ionizing radiation through the p38MAPK and NF-κB signaling pathway. Mol Med Rep (2017) 16:1216–22.  10.3892/mmr.2017.6689 PubMed DOI PMC

Li Y, Li L, Wu Z, Wang L, Wu Y, Li D, et al. Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo. Oncol Rep (2017) 38:325–35.  10.3892/or.2017.5665 PubMed DOI

Golding SE, Rosenberg E, Adams BR, Wignarajah S, Beckta JM, O'Connor MJ, et al. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle (2012) 11(6):1167–73.  10.4161/cc.11.6.19576 PubMed DOI PMC

Carruthers R, Ahmed SU, Strathdee K, Gomez-Roman N, Amoah-Buahin E, Watts C, et al. Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol Oncol (2015) 9:192–203. 10.1016/j.molonc.2014.08.003 PubMed DOI PMC

Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. Transl Oncol (2017) 10:190–6. 10.1016/j.tranon.2017.01.007 PubMed DOI PMC

Subhash VV, Tan SH, Yeo MS, Yan FL, Peethala PC, Liem N, et al. ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis. Mol Cancer Ther (2016) 15:3087–96. 10.1158/1535-7163.MCT-15-1002 PubMed DOI

Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, et al. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res (2019) 79(15):3940–51.  10.1158/0008-5472.can-19-0761 PubMed DOI PMC

Petersen LF, Klimowicz AC, Otsuka S, Elegbede AA, Petrillo SK, Williamson T, et al. Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC. Oncotarget (2017) 8:38326–36. 10.18632/oncotarget.16215 PubMed DOI PMC

Feng X, Li H, Dean M, Wilson HE, Kornaga E, Enwere EK, et al. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer. Breast Cancer Res (2015) 17(1):65. 10.1186/s13058-015-0575-2 PubMed DOI PMC

Ho CK, et al. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol (2017).  10.1016/j.ygyno.2016.12.025 PubMed DOI

Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, et al. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Int J Cancer (2017) 140:2587–95. 10.1002/ijc.30668 PubMed DOI

Lu Y, Gao J, Lu Y. Downregulated ku70 and ATM associated to poor prognosis in colorectal cancer among Chinese patients. Onco Targets Ther (2014) 7:1955–61. 10.2147/OTT.S67814 PubMed DOI PMC

Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, et al. Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget (2012) 3(11):1348–55. 10.18632/oncotarget.694 PubMed DOI PMC

Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, et al. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res (2014) 20:1865–72. 10.1158/1078-0432.CCR-13-1239 PubMed DOI PMC

Bueno RC, Canevari RA, Villacis RA, Domingues MA, Caldeira JR, Rocha RM, et al. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas. Ann Oncol (2014) 25(1):69–75. 10.1093/annonc/mdt421 PubMed DOI

Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, et al. Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol (2012) 48(8):698–702. 10.1016/j.oraloncology.2012.02.014 PubMed DOI

Ko JJ, Klimowicz AC, Jagdis A, Phan T, Laskin J, Lau HY, et al. ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. in. Head Neck (2016) 38:E384–91. 10.1002/hed.24004 PubMed DOI

Mhawech-Fauceglia P, Wang D, Kim G, Sharifian M, Chen X, Liu Q, et al. Expression of DNA repair proteins in endometrial cancer predicts disease outcome. Gynecol Oncol (2014) 132:593–8. 10.1016/j.ygyno.2014.02.002 PubMed DOI

Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, et al. The role of ATM and 53BP1 as predictive markers in cervical cancer. Int J Cancer (2012) 131(9):2056–66. 10.1002/ijc.27488 PubMed DOI PMC

Feng X, Li H, Kornaga EN, Dean M, Lees-Miller SP, Riabowol K, et al. Low Ki67 / high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer. Oncotarget (2016) 7(52):85798–812. 10.18632/oncotarget.12622 PubMed DOI PMC

Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol (2009) 27(19):3091–6.  10.1200/JCO.2008.19.9802 PubMed DOI PMC

Li C-C, Yang JC, Lu MC, Lee CL, Peng CY, Hsu WY, et al. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. Oncotarget (2015) 7(2):1947–59. 10.18632/oncotarget.6482 PubMed DOI PMC

Li CC, Yang JC, Lu MC, Lee CL, Peng CY, Hsu WY, et al. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. Oncotarget (2016) 7(2):1947–59.  10.18632/oncotarget.6482 PubMed DOI PMC

Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res (2018) 8(7):1307–16. PubMed PMC

Lee B, Lee HJ, Cho HY, Suh DH, Kim K, No JH, et al. Ataxia-telangiectasia and RAD3-related and ataxia-telangiectasia-mutated proteins in epithelial ovarian carcinoma: Their expression and clinical significance. Anticancer Res (2015) 35(7):3909–16. PubMed

Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol Oncol (2015) 9(3):569–85.  10.1016/j.molonc.2014.10.013 PubMed DOI PMC

Al-Kaabi MM, Alshareeda AT, Jerjees DA, Muftah AA, Green AR, Alsubhi NH, et al. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Br J Cancer (2015) 112(5):901–11. 10.1038/bjc.2014.576 PubMed DOI PMC

Kilpivaara O, Bartkova J, Eerola H, Syrjäkoski K, Vahteristo P, Lukas J, et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer (2005) 113(4):575–80. 10.1002/ijc.20638 PubMed DOI

Lee HE, Han N, Kim MA, Lee HS, Yang HK, Lee BL, et al. DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. Pathobiology (2013) 81(1):25–35. 10.1159/000351072 PubMed DOI

Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol (2004) 15(2):252–6.  10.1093/annonc/mdh073 PubMed DOI

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA, et al. High expression of Wee1 is associated with poor disease-free survival in Malignant Melanoma: Potential for targeted therapy. PloS One (2012) 7(6):e38254. 10.1371/journal.pone.0038254 PubMed DOI PMC

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA, et al. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol (2014) 135(1):118–24. 10.1016/j.ygyno.2014.07.102 PubMed DOI

Music D, Dahlrot RH, Hermansen SK, Hjelmborg J, de Stricker K, Hansen S, et al. Expression and prognostic value of the WEE1 kinase in gliomas. J Neurooncol (2016) 127(2):381–9. 10.1007/s11060-015-2050-4 PubMed DOI

Ge XC, Wu F, Li WT, Zhu XJ, Liu JW, Wang BL. Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncol Lett (2017) 13(6):4341–8.  10.3892/ol.2017.5984 PubMed DOI PMC

Seol HJ, Yoo HY, Jin J, Joo KM, Kim HS, Yoon SJ, et al. The expression of DNA damage checkpoint proteins and prognostic implication in metastatic brain tumors. Oncol Res (2011) 19(8–9):381–90.  10.3727/096504011X13123323849654 PubMed DOI

Stawinska M, Cygankiewicz A, Trzcinski R, Mik M, Dziki A, Krajewska WM. Alterations of Chk1 and Chk2 expression in colon cancer. Int J Colorectal Dis (2008) 23(12):1243–9. 10.1007/s00384-008-0551-8 PubMed DOI

Honrado E, Osorio A, Palacios J, Milne RL, Sánchez L, Díez O, et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol (2005) 23(30):7503–11. 10.1200/JCO.2005.01.3698 PubMed DOI

Bartkova J, Guldberg P, Grønbaek K, Koed K, Primdahl H, Møller K, et al. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene (2004) 23(52):8545–51. 10.1038/sj.onc.1207878 PubMed DOI

Zhang P, Wang J, Gao W, Yuan BZ, Rogers J, Reed E. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer (2004) 3:14.  10.1186/1476-4598-3-14 PubMed DOI PMC

Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun (2017) 8(1):1751  10.1038/s41467-017-01883-9 PubMed DOI PMC

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K. Expression and clinical significance of Wee1 in colorectal cancer. Tumour Biol (2016) 37(9):12133–40.  10.1007/s13277-016-5081-3 PubMed DOI

Magnussen G, I, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer (2013) 13:288. 10.1186/1471-2407-13-288 PubMed DOI PMC

PosthumaDeBoer J, Würdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer (2011) 11:156.  10.1186/1471-2407-11-156 PubMed DOI PMC